How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review (Q37665294)

21 August 2017

1 reference

title

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review (English)

1 reference

21 August 2017

1 reference

Phyllis I Spuls

1

1 reference

21 August 2017

Lidian L A Lecluse

2

1 reference

21 August 2017

Marie-Louise N F Poulsen

3

1 reference

21 August 2017

Jan D Bos

4

1 reference

21 August 2017

Robert S Stern

5

1 reference

21 August 2017

Tamar Nijsten

6

1 reference

21 August 2017

language of work or name

English

0 references

publication date

31 December 2009

1 reference

Journal of Investigative Dermatology

21 August 2017

published in

1 reference

21 August 2017

volume

130

1 reference

21 August 2017

issue

4

1 reference

21 August 2017

page(s)

933-943

1 reference

Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Understanding and evaluating clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Critical review of generic and dermatology-specific health-related quality of life instruments

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

A critical assessment of composite and coprimary endpoints: a complex problem

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

A quantitative definition of severe psoriasis for use in clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

The Self-Administered Psoriasis Area and Severity Index provides an objective measure of psoriasis severity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

The self-administered psoriasis area and severity index is valid and reliable

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Psoriasis assessment tools in clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Patient measurement of psoriasis disease severity with a structured instrument

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Reproducibility of clinical trials of topical glucocorticosteroids

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead-Sea

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Comparison of computer-aided design and rule of nines methods in the evaluation of the extent of body involvement in cutaneous lesions

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Psoriasis Area and Severity Index 50 as an endpoint in psoriasis trials: an unconvincing proposal

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

The Salford Psoriasis Index: an holistic measure of psoriasis severity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Physical and psychologic measures are necessary to assess overall psoriasis severity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Computer-aided measurement of psoriatic lesion area in a multicenter clinical trial--comparison to physician's estimations

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Assessment of skin erythema by eye, laser Doppler flowmeter, spectroradiometer, two-channel erythema meter and Minolta chroma meter

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

The rule of hand: 4 hand areas = 2 FTU = 1 g

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Randomized Clinical Trials for Psoriasis 1977–2000: The EDEN Survey

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

A comparison of subjective and objective measures of reduction of psoriasis with the use of ultrasound, reflectance colorimetry, computerized video image analysis, and nitric oxide production

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Safe psoriasis control: a new outcome measure for the composite assessment of the efficacy and safety of psoriasis treatment

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Measurement of involved surface area in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

https://api.crossref.org/works/10.1038%2FJID.2009.391

1 reference

7 January 2021

Psoriasis causes as much disability as other major medical diseases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Measures of Clinical Severity, Quality of Life, and Psychological Distress in Patients with Psoriasis: A Cluster Analysis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Performance of the self-administered psoriasis area and severity index in evaluating clinical and sociodemographic subgroups of patients with psoriasis.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Comparison of actual psoriasis surface area and the psoriasis area and severity index by the human eye and machine vision methods in following the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis - a structural equations modeling approach

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

What are the best outcome measurements for atopic eczema? A systematic review

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Colorimetric quantification of erythema--a comparison of two colorimeters (Lange Micro Color and Minolta Chroma Meter CR-200) with a clinical scoring scheme and laser-Doppler flowmetry.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Quality criteria were proposed for measurement properties of health status questionnaires

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

The ‘handprint’ approximates to 1% of the total body surface area whereas the ‘palm minus the fingers’ does not

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Assessment of area of involvement in skin disease: a study using schematic figure outlines

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

On the limitations of the psoriasis area and severity index (PASI)

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Assessment of severity score in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Objective assessment of involved surface area in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2009.391

7 January 2021

Identifiers

DOI

10.1038/JID.2009.391

1 reference

release_d4ekr7jrhna7do32llhcqggyee

21 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d4ekr7jrhna7do32llhcqggyee

24 November 2022

mapped directly with Wikidata item

1 reference